Data were pooled using the random-effects model. Two reviewers independently selected the studies and abstracted data. All nonhuman studies and case reports, studies evaluating patients with ischemic stroke requiring anticoagulation reversal or different dosing regimens of DOAC reversal agents, and mixed study groups with DOAC and warfarin were excluded.ĭata Extraction and Synthesis Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used for abstracting data and assessing data quality and validity. Study Selection The eligibility criteria were (1) adult patients (age ≥18 years) with ICH receiving treatment with a DOAC, (2) reversal of DOAC, and (3) reported safety and anticoagulation reversal outcomes. Objective To evaluate the safety and outcomes of DOAC reversal agents among patients with ICH.ĭata Sources PubMed, MEDLINE, The Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL databases were searched from inception through April 29, 2022.

The safety and outcome data of DOAC reversal agents in ICH are limited. Importance Direct oral anticoagulant (DOAC)–associated intracranial hemorrhage (ICH) has high morbidity and mortality.

Shared Decision Making and Communication.

Scientific Discovery and the Future of Medicine.

Health Care Economics, Insurance, Payment.

Clinical Implications of Basic Neuroscience.

Challenges in Clinical Electrocardiography.

Andexanet cost